Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus

被引:472
作者
Valencia, Xavier [1 ]
Yarboro, Cheryl
Illei, Gabor
Lipsky, Peter E.
机构
[1] NIAMSD, Autoimmun Branch, NIH, Bethesda, MD 20892 USA
[2] NIAMSD, Off Clin Director, NIH, Bethesda, MD 20892 USA
[3] Natl Inst Dent & Craniofacial Res, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.178.4.2579
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
CD4(+)CD25(+) T regulatory cells (Tregs) play an essential role in maintaining immunologic homeostasis and preventing autoimmunity. Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by a loss of tolerance to nuclear components. We hypothesized that altered function of CD4(+)CD25(high) Tregs might play a role in the breakdown of immunologic self-tolerance in patients with SLE. In this study, we report a significant decrease in the suppressive function of CD4(+)CD25(high) Tregs from peripheral blood of patients with active SLE as compared with normal donors and patients with inactive SLE. Notably, CD4(+)CD25(high) Tregs isolated from patients with active SLE expressed reduced levels of FoxP3 mRNA and protein and poorly suppressed the proliferation and cytokine secretion of CD4(+) effector T cells in vitro. In contrast, the expression of FoxP3 mRNA and protein and in vitro suppression of the proliferation of CD4(+) effector T cells by Tregs isolated from inactive SLE patients, was comparable to that of normal individuals. In vitro activation of CD4(+)CD25(high) Tregs from patients with active SLE increased FoxP3 mRNA and protein expression and restored their suppressive function. These data are the first to demonstrate a reversible defect in CD4(+)CD25(high) Treg function in patients with active SLE, and suggest that strategies to enhance the function of these cells might benefit patients with this autoimmune disease.
引用
收藏
页码:2579 / 2588
页数:10
相关论文
共 44 条
[1]   Regulatory T cells in patients with systemic lupus erythematosus [J].
Alvarado-Sanchez, Brenda ;
Hernandez-Castro, Berenice ;
Portales-Perez, Diana ;
Baranda, Lourdes ;
Layseca-Espinosa, Esther ;
Abud-Mendoza, Carlos ;
Cubillas-Tejeda, Ana C. ;
Gonzalez-Amaro, Roberto .
JOURNAL OF AUTOIMMUNITY, 2006, 27 (02) :110-118
[2]   Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention [J].
Aringer, M ;
Smolen, J .
LUPUS, 2004, 13 (05) :344-347
[3]   Inhibition of human CD4+CD25+high regulatory T cell function [J].
Baecher-Allan, C ;
Viglietta, V ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2002, 169 (11) :6210-6217
[4]   CD4+CD25high regulatory cells in human peripheral blood [J].
Baecher-Allan, C ;
Brown, JA ;
Freeman, GJ ;
Hafler, DA .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1245-1253
[5]   The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3 [J].
Bennett, CL ;
Christie, J ;
Ramsdell, F ;
Brunkow, ME ;
Ferguson, PJ ;
Whitesell, L ;
Kelly, TE ;
Saulsbury, FT ;
Chance, PF ;
Ochs, HD .
NATURE GENETICS, 2001, 27 (01) :20-21
[6]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[7]  
COHEN PL, 1993, J INVEST DERMATOL, V100, pS69, DOI 10.1038/jid.1993.26
[8]   Quantification of regulatory T cells in patients with systemic lupus erythematosus [J].
Crispin, JC ;
Martínez, A ;
Alcocer-Varela, J .
JOURNAL OF AUTOIMMUNITY, 2003, 21 (03) :273-276
[9]   GENERATION AND BIOLOGICAL CHARACTERIZATION OF MEMBRANE-BOUND, UNCLEAVABLE MURINE TUMOR-NECROSIS-FACTOR [J].
DECOSTER, E ;
VANHAESEBROECK, B ;
VANDENABEELE, P ;
GROOTEN, J ;
FIERS, W .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (31) :18473-18478
[10]   A function for interleukin 2 in Foxp3-expressing regulatory T cells [J].
Fontenot, JD ;
Rasmussen, JP ;
Gavin, MA ;
Rudensky, AY .
NATURE IMMUNOLOGY, 2005, 6 (11) :1142-1151